Clinical Trial

. 2018 Oct 23;18(1):1030.

doi: 10.1186/s12885-018-4916-2.

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Shankar Siva^{1

2}, Brent Chesson³, Mathias Bressel³, David Pryor⁴, Braden Higgs⁵, Hayley M Reynolds³, Nicholas Hardcastle³, Rebecca Montgomery⁶, Ben Vanneste⁷, Vincent Khoo⁸, Jeremy Ruben⁹, Eddie Lau¹⁰, Michael S Hofman³, Richard De Abreu Lourenco¹¹, Swetha Sridharan¹², Nicholas R Brook⁶, Jarad Martin¹², Nathan Lawrentschuk^{3

13}, Tomas Kron³, Farshad Foroudi¹⁴

Affiliations

¹ Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australia. shankar.siva@petermac.org.
² University of Melbourne, Royal Parade, Parkville, 8006, Australia. shankar.siva@petermac.org.
³ Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australia.
⁴ Princess Alexandra Hospital, Brisbane, QLD, Australia.
⁵ University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
⁶ Trans Tasman Radiation Oncology Group (TROG), Waratah, Australia.
⁷ MAASTRO Clinic, Maastricht, The Netherlands.
⁸ Royal Marsden Hospital, London, UK.
⁹ Alfred Health and Monash University, 55 Commercial Rd, Melbourne, 3004, Australia.
¹⁰ Austin Health, Heidelberg, 3084, Australia.
¹¹ Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia.
¹² Calvary Mater Newcastle, Newcastle, NSW, Australia.
¹³ University of Melbourne, Royal Parade, Parkville, 8006, Australia.
¹⁴ Radiation Oncology, Austin Health, Heidelberg, Australia.

PMID: 30352550
PMCID: PMC6199711
DOI: 10.1186/s12885-018-4916-2

Clinical Trial

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Shankar Siva et al. BMC Cancer. 2018.

. 2018 Oct 23;18(1):1030.

doi: 10.1186/s12885-018-4916-2.

Authors

Affiliations

¹ Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australia. shankar.siva@petermac.org.
² University of Melbourne, Royal Parade, Parkville, 8006, Australia. shankar.siva@petermac.org.
³ Peter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australia.
⁴ Princess Alexandra Hospital, Brisbane, QLD, Australia.
⁵ University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
⁶ Trans Tasman Radiation Oncology Group (TROG), Waratah, Australia.
⁷ MAASTRO Clinic, Maastricht, The Netherlands.
⁸ Royal Marsden Hospital, London, UK.
⁹ Alfred Health and Monash University, 55 Commercial Rd, Melbourne, 3004, Australia.
¹⁰ Austin Health, Heidelberg, 3084, Australia.
¹¹ Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia.
¹² Calvary Mater Newcastle, Newcastle, NSW, Australia.
¹³ University of Melbourne, Royal Parade, Parkville, 8006, Australia.
¹⁴ Radiation Oncology, Austin Health, Heidelberg, Australia.

PMID: 30352550
PMCID: PMC6199711
DOI: 10.1186/s12885-018-4916-2

Abstract

Background: Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC.

Methods: FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over 3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline surgery. Radiotherapy treatment planning is undertaken using four dimensional CT scanning to incorporate the impact of respiratory motion. Treatment must be delivered using a conformal or intensity modulated technique including IMRT, VMAT, Cyberknife or Tomotherapy. The trial includes two alternate fractionation schedules based on tumour size: for tumours ≤4 cm in maximum diameter a single fraction of 26Gy is delivered; and for tumours > 4 cm in maximum diameter 42Gy in three fractions is delivered. The primary outcome of the study is to estimate the efficacy of SABR for primary RCC. Secondary objectives include estimating tolerability, characterising overall survival and cancer specific survival, estimating the distant failure rate, describing toxicity and renal function changes after SABR, and assessment of cost-effectiveness of SABR compared with current therapies.

Discussion: The present study design allows for multicentre prospective validation of the efficacy of SABR for primary RCC that has been observed from prior single institutional and retrospective series. The study also allows assessment of treatment related toxicity, overall survival, cancer specific survival, freedom from distant failure and renal function post therapy.

Trial registration: Clinicaltrials.gov NCT02613819 , registered Nov 25th 2015.

Keywords: Ablation; Adrenal; Kidney; Metastases; Nephrectomy; RCC; SABR; SBRT.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethical approval has been obtained for the clinical sites currently recruiting to this multicentre study at the time of writing;

Princess Alexandra Hospital, Peter MacCallum Cancer Centre, Royal Adelaide Hospital, Royal North Shore Hospital, Alfred Health, Calvary Mater Newcastle.

Royal Brisbane and Women’s Hospital, South Western Sydney Local Health District (Liverpool and Campbelltown Hospitals).

Consent for publication

Not applicable as this protocol publication does not include patient information.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

**Fig. 1**
Axial 3D conformal treatment plan of SABR for right kidney (A) and 3D reconstruction (B) showing multiple beam angles resulting in high-doses wrapping tightly around the target

See this image and copyright information in PMC

References

1. AIHW A: Cancer in Australia: an overview, 2014. AIHW, Cancer Series no 90, Cat no CAN 88 Canberra 2014.
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
1. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, Shippee ND, Erwin PJ, Costello BA, Chow GK. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012;188(1):51–57. doi: 10.1016/j.juro.2012.03.006. - DOI - PubMed
1. Demirjian S, Lane BR, Derweesh IH, Takagi T, Fergany A, Campbell SC. Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. J Urol. 2014;192:1057. doi: 10.1016/j.juro.2014.04.016. - DOI - PubMed
1. Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, Chen MY. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. Am J Roentgenol. 2004;183(1):201–207. doi: 10.2214/ajr.183.1.1830201. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Affiliations

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Authors

Affiliations

Abstract

Conflict of interest statement

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Figures

References

Publication types

MeSH terms

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical